A generalist perspective on second generation antipsychotics;Allgemeinmedizinische aspekte der therapie mit antipsychotika der zweiten generation

Deutsches Arzteblatt

Volumn 103, Issue 42, 2006, Pages

  Agelink, Marcus W ^a,b,c   Kornischka, Jürgen ^b,c   Cordes, Joachim ^d   Klimke, Ansgar ^e   Hauner, Hans ^f   Ziegler, Dan ^d  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b Klinikum Herford   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d HEINRICH HEINE UNIVERSITY   (Germany)

^e GOETHE UNIVERSITY   (Germany)

^f TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Antipsychotics; Diabetes mellitus; Metabolic syndrome; Neuroleptics; Treatment

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CHOLESTEROL; CLOZAPINE; LIPID; NEUROLEPTIC AGENT; OLANZAPINE; PROLACTIN; QUETIAPINE; RISPERIDONE; TRIACYLGLYCEROL; ZIPRASIDONE; ZOTEPINE;

AGRANULOCYTOSIS; ARTICLE; DIABETES MELLITUS; DYSLIPIDEMIA; ELECTROCARDIOGRAM; HUMAN; MEDICAL LITERATURE; MEDICAL RESEARCH; METABOLIC SYNDROME X; QT INTERVAL; REPOLARIZATION;

EID: 33750730597     PISSN: 00121207     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Windgassen K, Bick O: Fortschritte in der neuroleptischen Schizophreniebehandlung. Dtsch Arztebl 2004; 101(48): A3270-5.
2. Holt RJ, Reveler RC, Byrne CD: Schizophrenia, the metabolic syndrome and diabetes. Diabet Med 2004; 21: 515-23.
3. McEvoy JP, Meyer JM, Goff DC et al.: Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effictiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005; 80: 19-32.
4. Himmerich H, Schuld A, Pollmächer T: Gewichtszunahme unter Psychopharmakotherapie. Dtsch Arztebl 2005; 102(31-32): A 2172-7.
5. Allison DB, Mentore JL, Heo M et al.: Antipsychotic-induced weight gain: a comprehensive research synthesis, Am J Psychiatry 1999; 156: 1686-96.
6. Lieberman JA, Stroup TS, McEvoy PJ et al.: Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl Med J 2005; 353: 1209-23.
7. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27: 596-601.
8. Newcomer JW: Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19: (Suppl 1)1-93.
9. Hummer M, Huber J: Hyperprolactinaemia and antipsychotic therapy in schizophrenia. Curr Med Res Opin 2004; 20: 189-97.
10. 2 receptor occupancy in antipsychotic drugs-treated patiens. J Clin Psychopharmacol 1998; 18: 305-10.
11. Straus SM, Bleumink GS, Dieleman JP et al.: Antipsychotics and the risk of sudden cardiac death. Arch Intern Med 2004; 164: 1293-7.
12. Haddad PM, Anderson IM: Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs 2002; 62: 1649-71.
13. Glassman AH, Bigger JT: Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001; 158: 1774-84.
14. Haverkamp W, Haverkamp F, Breithardt G: Medikamentenbedingte QT-Verlängerung und Torsade de pointes. Dtsch Arztebl 2002; 99(28-29): A 1972-9.
15. Agelink MW, Majewski T, Wurthmann C et al.: Effects of newer atypical antipsychotics on autonomie neurocardiac function: a comparison between amisulpride, olanzapine, sertindole, and clozapine. J Clin Psychopharmacol 2001; 21: 8-13.
16. Baumann P, Hiemke C, Ulrich S et al., The AGNP-TDM Expert Group Consensus Guidelines: Therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 2004; 37: 243-65.
17. Brodaty H, Ames D, Snowden J et al.: A randomized placebo controlled trial of risperidone for the treatment of aggression, agitation, and psychosis in dementia. J Clin Psychiatry 2003; 64: 134-43.
18. Wooltorton E: Risperidone (Risperdal): increased rate of cerebrocascular events in dementia trials. CMAJ 2002; 167: 1269-70.
19. Wooltorton E: Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials. CMAJ 2004; 170: 1395.
20. Ballard C, Waite J: The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev 2006: CD003476.
21. Schneider LS, Dagerman KS, Insel P: Risk of death with atypical antipsychotic drugs treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005; 294: 1934-43.
22. Liperoti R, Gambassi G, Lapane KL et al.: Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics. J Clin Psychiatry 2005; 66: 1090-6.
23. Herrmann N, Mamdani M, Lanctot KL: Atypical antipsychotics and risk of cerebrovascular accidents. Am J Psychiatry 2004; 161: 1113-5.
24. Gill SS, Rochon PA, Herrmann N et al.: Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ 2005; 330.
25. Benkert O, Hippius H: Kompendium der psychiatrischen Pharmakotherapie. 5. Auflage. Heidelberg: Springer Verlag, Heidelberg; 205-6.